G protein-coupled receptor
μ-opioid receptor
Mu opioid receptor
- GeneOPRM1
- FamilyOpioid receptors
- GroupOpioid receptors
Opioids act through three classes of receptors, μ, δ and κ. The μ-opioid receptor is the molecular target of morphine in the living animal, and morphine does not act without it.1 Opiates were shown to bind to membrane receptors in the brain in 1973, and the binding sites were named mu, delta and kappa a few years later. The first opioid receptor gene was isolated by expression cloning in 1992, and because of strong sequence homology the whole gene family was cloned within the following two years. Opioid receptors are Gi/o-coupled G protein-coupled receptors.2,3 A review of the last 35 years describes how the picture of the morphine-like drugs and their receptors changed. Early pharmacological studies identified three major classes of receptors, helped by the discovery of the endogenous opioid peptides. Molecular biology then revealed a complexity that had not been appreciated before. The idea of multiple opioid receptors was first suggested almost 50 years before the review.4
In the rat brain, cells with mu receptor mRNA are found in the olfactory bulb, caudate-putamen, nucleus accumbens, septum, most thalamic nuclei, hippocampus and amygdala, and also in the central gray, the raphe nuclei, the locus coeruleus, the nucleus of the solitary tract, the spinal cord and the dorsal root ganglia. Autoradiography found dense mu binding in the anterior cingulate cortex, neocortex, amygdala, hippocampus, nucleus accumbens, caudate putamen, thalamus, habenula, interpeduncular nucleus, the pars compacta of the substantia nigra, the colliculi and the raphe nuclei. Each of the three receptor mRNAs had its own distribution, which agreed well with the known binding.5,6
Opioid receptors regulate pain, reward, mood, stress, gastrointestinal transport and respiration. Agonists can stabilise different active states of a receptor, which is called ligand-directed signalling or biased agonism. For the mu and delta receptors, most of the reported ligand-selective behavioural effects are seen as differences in the adaptation to repeated drug administration.3
In mice without the receptor, morphine relieves no pain, causes no place preference and produces no physical dependence.1 In such mice, a high dose of morphine also no longer reduced breathing, while it did in normal mice.7 In patients, opioid pain treatment is generally safe, with 0.5 percent or less of events from respiratory depression, but fatalities are regularly reported. The only treatment available to reverse the depression is naloxone. Opioids with a high receptor affinity need larger naloxone concentrations or a continuous infusion before the reversal sets in. Experimental approaches to prevent the depression without affecting analgesia include serotonin agonists, ampakines and the antibiotic minocycline.8
Sources (8)
- Matthes et al. 1996Matthes HW, Maldonado R, Simonin F, et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene Nature
- Kieffer et al. 2009Kieffer BL, Evans CJ (2009) Opioid receptors: from binding sites to visible molecules in vivo Neuropharmacology
- Pradhan et al. 2012Pradhan AA, Smith ML, Kieffer BL, et al. (2012) Ligand-directed signalling within the opioid receptor family Br J Pharmacol
- Pasternak et al. 2013Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept Pharmacol Rev
- Mansour et al. 1994Mansour A, Fox CA, Burke S, et al. (1994) Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study J Comp Neurol
- Mansour et al. 1987Mansour A, Khachaturian H, Lewis ME, et al. (1987) Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain J Neurosci
- Dahan et al. 2001Dahan A, Sarton E, Teppema L, et al. (2001) Anesthetic potency and influence of morphine and sevoflurane on respiration in mu-opioid receptor knockout mice Anesthesiology
- Dahan et al. 2010Dahan A, Aarts L, Smith TW (2010) Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression Anesthesiology
Binding affinity (Kᵢ)
16 substances, 28 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.
Human
14 measurements
Buprenorphine0.22 nMVolpe et al. 2011 · 3 reports
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
- Range
- 0.22–1.5 nM in 3 reports
Reported values disagree and no value is established. 3 reports in all, 0.22–1.5 nM.
Sources and values behind the range, same assay family Report Value Where Volpe et al. 2011 0.22 nM Table 2 Toll et al. 1998 1.5 nM Table 5 Obeng et al. 2021 0.90 nM Table 2 Hydromorphone0.37 nMVolpe et al. 2011 · 2 reports
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
- Range
- 0.28–0.37 nM in 2 reports
Sources and values behind the range, same assay family Report Value Where Volpe et al. 2011 0.37 nM Table 2 Wentland et al. 2009 0.28 nM Table 1 Oxymorphone0.41 nMVolpe et al. 2011
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
Morphine1.2 nMVolpe et al. 2011 · 6 reports
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
- Range
- 0.62–415 nM in 6 reports
This is the best-supported value. Other reports differ. 7 reports in all, 0.62–415 nM.
Sources and values behind the range, same assay family Report Value Where Volpe et al. 2011 1.2 nM Table 2 Neumeyer et al. 2012 0.88 nM Table 2 Gillen et al. 2000 0.62 nM, 415 nM Table 1, Table 2 Toll et al. 1998 1.1 nM Table 5 Obeng et al. 2021 4.2 nM Table 2 Fentanyl1.3 nMVolpe et al. 2011 · 4 reports
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
- Range
- 0.70–355 nM in 4 reports
Reported values disagree and no value is established. 4 reports in all, 0.70–355 nM.
Sources and values behind the range, same assay family Report Value Where Volpe et al. 2011 1.3 nM Table 2 Gillen et al. 2000 355 nM Table 2 Toll et al. 1998 0.70 nM Table 5 Obeng et al. 2021 8.0 nM Table 2 Methadone3.4 nMVolpe et al. 2011 · 2 reports
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
- Range
- 0.60–3.4 nM in 2 reports
Reported values disagree and no value is established. 2 reports in all, 0.60–3.4 nM.
Sources and values behind the range, same assay family Report Value Where Volpe et al. 2011 3.4 nM Table 2 Toll et al. 1998 0.60 nM Table 5 Oxycodone16 nMLalovic et al. 2006 · 2 reports
- Assay
- human MOR1 membranes from stably transfected cells, [3H]diprenorphine displacement
- Shown value from
- Lalovic et al. 2006, Table I
- Range
- 16–26 nM in 2 reports
- Error
- ± 2.9 SD, n = 2
Sources and values behind the range, same assay family Report Value Where Volpe et al. 2011 26 nM Table 2 Lalovic et al. 2006 16 nM Table I Hydrocodone42 nMVolpe et al. 2011 · 2 reports
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
- Range
- 9.5–42 nM in 2 reports
Reported values disagree and no value is established. 2 reports in all, 9.5–42 nM.
Sources and values behind the range, same assay family Report Value Where Volpe et al. 2011 42 nM Table 2 Neumeyer et al. 2012 9.5 nM Table 2 7-Hydroxymitragynine47 nMKruegel et al. 2016 · 2 reports
- Assay
- cells expressing human MOR, opioid receptor binding
- Shown value from
- Kruegel et al. 2016, Table 2
- Range
- 47–78 nM in 2 reports
- Error
- ± 18 SEM
Sources and values behind the range, same assay family Report Value Where Obeng et al. 2021 78 nM Table 2 Kruegel et al. 2016 47 nM Table 2 Tapentadol160 nMTzschentke et al. 2007 · 2 reports
- Assay
- human recombinant MOR, [3H]naloxone-type competition (Fig. 2A)
- Shown value from
- Tzschentke et al. 2007, Results text (Fig. 2A)
Sources and values behind the range, same assay family Report Value Where Tzschentke et al. 2007 160 nM Results text (Fig. 2A) Roulet et al. 2021 160 nM Table 1 Mitragynine233 nMKruegel et al. 2016 · 2 reports
- Assay
- cells expressing human MOR, opioid receptor binding
- Shown value from
- Kruegel et al. 2016, Table 2
- Range
- 233–709 nM in 2 reports
- Error
- ± 48 SEM
Reported values disagree and no value is established. 2 reports in all, 233–709 nM.
Sources and values behind the range, same assay family Report Value Where Obeng et al. 2021 709 nM Table 2 Kruegel et al. 2016 233 nM Table 2 Pethidine450 nMVolpe et al. 2011
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
Codeine734 nMVolpe et al. 2011 · 2 reports
- Assay
- recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
- Shown value from
- Volpe et al. 2011, Table 2
- Range
- 135–734 nM in 2 reports
Reported values disagree and no value is established. 2 reports in all, 135–734 nM.
Sources and values behind the range, same assay family Report Value Where Volpe et al. 2011 734 nM Table 2 Toll et al. 1998 135 nM Table 5 Tramadol2400 nMGillen et al. 2000 · 2 reports
- Assay
- cloned human MOR in CHO membranes, [3H]naloxone competition, low-salt conditions
- Shown value from
- Gillen et al. 2000, Table 1
- Error
- ± 1100 SD
Sources and values behind the range, same assay family Report Value Where Gillen et al. 2000 2400 nM Table 1 Roulet et al. 2021 2400 nM Table 1
Guinea pig
5 measurements
Fentanyl1.0 nMToll et al. 1998
- Assay
- guinea-pig brain membranes, [3H]DAMGO competition
- Shown value from
- Toll et al. 1998, Table 5
- Error
- ± 0.10 SD
Buprenorphine1.3 nMToll et al. 1998
- Assay
- guinea-pig brain membranes, [3H]DAMGO competition
- Shown value from
- Toll et al. 1998, Table 5
- Error
- ± 0.15 SD
Methadone1.4 nMToll et al. 1998
- Assay
- guinea-pig brain membranes, [3H]DAMGO competition
- Shown value from
- Toll et al. 1998, Table 5
- Error
- ± 0.05 SD
Morphine2.0 nMToll et al. 1998
- Assay
- guinea-pig brain membranes, [3H]DAMGO competition
- Shown value from
- Toll et al. 1998, Table 5
- Error
- ± 0.30 SD
Codeine152 nMToll et al. 1998
- Assay
- guinea-pig brain membranes, [3H]DAMGO competition
- Shown value from
- Toll et al. 1998, Table 5
- Error
- ± 33 SD
Rat
8 measurements
Buprenorphine0.08 nMHuang et al. 2001
- Assay
- recombinant rat MOR in CHO membranes, [3H]diprenorphine competition
- Shown value from
- Huang et al. 2001, Table 1
- Error
- ± 0.02 SEM, n = 4
Oxymorphone0.97 nMBen Haddou et al. 2014
- Assay
- native rat brain membranes, [3H]DAMGO competition
- Shown value from
- Ben Haddou et al. 2014, Table 1
- Error
- ± 0.05 SEM
Morphine6.5 nMBen Haddou et al. 2014 · 2 reports
- Assay
- native rat brain membranes, [3H]DAMGO competition
- Shown value from
- Ben Haddou et al. 2014, Table 1
- Range
- 2.2–6.5 nM in 2 reports
- Error
- ± 0.74 SEM
Sources and values behind the range, same assay family Report Value Where Ben Haddou et al. 2014 6.5 nM Table 1 Tzschentke et al. 2007 2.2 nM Table 1 Oxycodone18 nMMonory et al. 1999 · 3 reports
- Assay
- rat brain membranes, displacement of [3H]DAMGO
- Shown value from
- Monory et al. 1999, Table II
- Range
- 15–25 nM in 3 reports
3-HO-PCP39 nMItzhak et al. 1981
- Assay
- rat brain homogenate (minus cerebellum), [3H]morphine 1.13 nM, mu site
- Shown value from
- Itzhak et al. 1981, Table 1B
Tapentadol96 nMTzschentke et al. 2007
- Assay
- rat opioid receptor binding assay
- Shown value from
- Tzschentke et al. 2007, Table 1
- Error
- ± 9.0 SEM
Codeine1300 nMTzschentke et al. 2007
- Assay
- rat opioid receptor binding assay
- Shown value from
- Tzschentke et al. 2007, Table 1
- Error
- ± 500 SEM
Unspecified
1 measurement
Mitragynine204 nMLydecker et al. 2016
- Assay
- MOR opioid receptor binding, quoted in a review table (original assay not restated)
- Shown value from
- Lydecker et al. 2016, Table 1
Functional potency (EC₅₀)
8 substances, 10 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.
Human
8 measurements
Buprenorphine2.3 nMToll et al. 1998 · 2 reports
- Assay
- human MOR-CHO cell membranes, [35S]GTPgammaS binding
- Shown value from
- Toll et al. 1998, Table 7
- Range
- 2.3–16 nM in 2 reports
- Error
- ± 1.7 SD
- Emax
- 66.0 ± 36.0%
Reported values disagree and no value is established. 2 reports in all, 2.3–16 nM.
Sources and values behind the range, same assay family Report Value Where Toll et al. 1998 2.3 nM Table 7 Obeng et al. 2021 16 nM Table 3 Oxymorphone4.4 nMBen Haddou et al. 2014
- Assay
- CHO cells expressing human opioid receptor, [35S]GTPγS functional assay
- Shown value from
- Ben Haddou et al. 2014, Table 2
- Error
- ± 0.76 SEM
- Emax
- 98.0 ± 1.0%
Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 4.4–44 nM.
Methadone27 nMToll et al. 1998
- Assay
- human MOR-CHO cell membranes, [35S]GTPgammaS binding
- Shown value from
- Toll et al. 1998, Table 7
- Error
- ± 14 SD
- Emax
- 116.0 ± 20.0%
Fentanyl28 nMObeng et al. 2021 · 4 reports
- Assay
- CHO cells expressing human MOR, [35S]GTPγS binding
- Shown value from
- Obeng et al. 2021, Table 3
- Range
- 8.1–110 nM in 4 reports
- Emax
- 110.0%
Reported values disagree and no value is established. 5 reports in all, 8.1–110 nM.
Sources and values behind the range, same assay family Report Value Where Gillen et al. 2000 110 nM Table 2 Toll et al. 1998 8.1 nM Table 7 Obeng et al. 2021 28 nM Table 3 Schmid et al. 2017 43 nM Table 1 Morphine34 nMBen Haddou et al. 2014 · 6 reports
- Assay
- CHO cells expressing human opioid receptor, [35S]GTPγS functional assay
- Shown value from
- Ben Haddou et al. 2014, Table 2
- Range
- 16–125 nM in 6 reports
- Error
- ± 5.1 SEM
- Emax
- 89.0 ± 17.0%
Reported values disagree and no value is established. 8 reports in all, 16–372 nM.
Sources and values behind the range, same assay family Report Value Where Ben Haddou et al. 2014 34 nM Table 2 Tzschentke et al. 2007 22 nM Results / Fig. 3 Gillen et al. 2000 118 nM Table 2 Toll et al. 1998 16 nM Table 7 Obeng et al. 2021 125 nM Table 3 Schmid et al. 2017 64 nM Table 1 7-Hydroxymitragynine43 nMObeng et al. 2021
- Assay
- CHO cells expressing human MOR, [35S]GTPγS binding
- Shown value from
- Obeng et al. 2021, Table 3
- Emax
- 41.3%
Oxycodone343 nMLalovic et al. 2006
- Assay
- human MOR1 membranes, [35S]GTPgammaS binding
- Shown value from
- Lalovic et al. 2006, Table I
- Error
- ± 7.9 SD, n = 2
Tapentadol670 nMTzschentke et al. 2007 · 2 reports
- Assay
- recombinant human MOR, [35S]GTPγS functional assay
- Shown value from
- Tzschentke et al. 2007, Results / Fig. 3
- Error
- ± 150 SEM
- Emax
- 88.0%
Sources and values behind the range, same assay family Report Value Where Tzschentke et al. 2007 670 nM Results / Fig. 3 Roulet et al. 2021 670 nM Table 1
Mouse
1 measurement
7-Hydroxymitragynine38 nMKruegel et al. 2016
- Assay
- mouse MOR, G protein BRET assay, agonist mode (relative to DAMGO)
- Shown value from
- Kruegel et al. 2016, Supplement Table S1
- Emax
- 23.0%
Rat
1 measurement
Buprenorphine0.08 nMHuang et al. 2001
- Assay
- recombinant rat MOR in CHO membranes, [35S]GTPgammaS functional assay
- Shown value from
- Huang et al. 2001, Table 2
- Error
- ± 0.01 SEM
- Emax
- 38.0 ± 8.0%
Also reported to act here
Substances reported to act here, without a displayed value.
Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.